CollabRx Releases Second Generation Lung Cancer Clinical Decision Support Tool for Oncologists

CollabRx Releases Second Generation Lung Cancer Clinical Decision Support Tool
for Oncologists

SAN FRANCISCO, Feb. 7, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX)
today announced the release of a new version of its Therapy Finder™application
("app") for lung cancer. The lung cancer Therapy Finder™app is a web-based
decision support tool that enables oncologists to take into account the
genetics of a patient's tumor when determining a treatment plan. The newest
lung cancer Therapy Finder™ is currently freely available at the company's
website and via distribution partners such as MedPage Today, Everyday Health's
physician portal
(http://www.medpagetoday.com/resource-center/lung-cancer-therapy/therapy-finder).

This "second generation" version of the Therapy Finder™ incorporates into its
proprietary rules-based algorithm and decision tables the results of recent
advances in lung cancer clinical and translational research by addressing the
ROS1 biomarker as a potentially relevant molecular subtype and diagnostic test
for lung cancer.Patients who are ROS1-positive may be candidates for the
Pfizer c-MET/ALK inhibitor Xalkori (crizotinib) and other ALK inhibitors
available in clinical trials.Other significant updates include additional
information and clinical context of the AstraZeneca investigational drug
selumetinib.

The app content is kept dynamically up-to-date by internal CollabRx scientists
using the company's proprietary semantic integration platform, a technology
developed by CollabRx to enable the efficient and semi-automated gathering,
annotation, and curation of the world's knowledge on molecular medicine for
oncology.In support of these activities, CollabRx is advised by an
independent board of independent lung cancer experts, led by Ravi Salgia, MD,
PhD, a professor of Medicine at the University of Chicago.Other lung cancer
expert advisory board members are affiliated with hospitals and cancer
treatment centers at the University of Colorado, Harvard Medical School,
University of Pittsburgh, Johns Hopkins Medical School, The Ohio State
University, and the Medical University of South Carolina.Many of these
advisors use the lung cancer Therapy Finder™ app in promoting
patient/physician engagement when treating lung cancer patients at their own
institutions.

"Therapy Finder™ apps are the first of a larger set of related products being
developed by CollabRx to support physician clinical decision making," said
Thomas Mika, President & CEO of CollabRx. "We are developing additional tools
for all common cancer types and extending their reach to address issues
important to pathologists and diagnostic laboratories, as well as physicians
treating patients with earlier stage disease and the prevention and early
detection of cancer, in support of our overall strategy to be the primary
source for clinically-relevant, actionable information for use by physicians
at the point of care."

About CollabRx

CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert
systems to inform health care decision-making. CollabRx uses information
technology to aggregate and contextualize the world's knowledge on
genomics-based medicine with specific insights from the nation's top cancer
experts starting with the area of greatest need: advanced cancers in patients
who have effectively exhausted the standard of care. More information may be
obtained at http://www.collabrx.com.

The CollabRx, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=16990

CONTACT: Thomas R. Mika, CEO
         CollabRx, Inc.
         415-248-5350
        
         Robert Ferri Partners, LLC
         Robert Ferri
         (415) 575-1589 (direct)
         robert.ferri@robertferri.com

CollabRx, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.